|
Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ercp post hoc efficacy and cost-benefit analyses using prospective clinical trial data |
Elmunzer BJ, Higgins PD, Saini SD, Scheiman JM, Parker RA, Chak A, Romagnuolo J, Mosler P, Hayward RA, Elta GH, Korsnes SJ, Schmidt SE, Sherman S, Lehman GA, Fogel EL |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Elmunzer BJ, Higgins PD, Saini SD, Scheiman JM, Parker RA, Chak A, Romagnuolo J, Mosler P, Hayward RA, Elta GH, Korsnes SJ, Schmidt SE, Sherman S, Lehman GA, Fogel EL. Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ercp post hoc efficacy and cost-benefit analyses using prospective clinical trial data. American Journal of Gastroenterology 2013; 108(3): 410-415 Indexing Status Subject indexing assigned by NLM MeSH Administration, Rectal; Adult; Aged; Cholangiopancreatography, Endoscopic Retrograde /adverse effects /economics; Cost-Benefit Analysis; Female; Humans; Indomethacin /administration & Male; Middle Aged; Pancreatitis /economics /etiology /prevention & Prospective Studies; Retrospective Studies; Risk Factors; Stents /economics; Treatment Outcome; control; dosage /economics /therapeutic use AccessionNumber 22013014870 Date bibliographic record published 29/10/2014 |
|
|
|